Daxor Corporation (DXR)

[surf1944]

8:39AM Daxor reports of a study comparing direct blood volume measurement with a non-invasive hemoglobin monitor in Critically Ill Surgical Patients; results show possibility to have a variation of ~+/-4 hematocrit points (DXR) 7.78 : Co announces study from The Queen's Medical Center in Hawaii involved 54 patients who had their hemoglobin/hematocrits compared to results from blood samples at the central laboratory as well as the results of normalized hematocrits determined actual blood volume measurements using the Daxor BVA-100.

Study observations

The findings of the study showed there was a better correlation with the non-invasive hemoglobin measurements and the measurements obtained from actual direct blood volume measurement.
There was a wider scatter of results when the non-invasive instrument was compared to results from the central laboratory.
The results of this study show that when combining the results of the Pulse CO-Oximetry instrument with the variation from the true normalized hematocrit, it is possible to have a variation of approximately +/-4 hematocrit points.
This can translate into a clinical error of estimating the patient's blood volume status of +/-18%. Septic patients have reported death rates of 20 - 40%.
These results, combined with other published studies, have demonstrated from other institutions that physicians have a relatively low degree of accuracy in assessing a patient's blood volume status from indirect measures.
Conclusions
The ability to obtain continuous hemoglobin which can be converted into hematocrit measurements has the potential for monitoring major shifts in blood volume.
However, such changes have not only limited value but can be highly misleading without an actual measurement of a patient's blood volume.